



500 Linden Oaks  
Rochester, New York 14625

**FOR IMMEDIATE RELEASE**

**CONTACT: Investor Relations Contact:**  
BPC Financial Marketing  
John Baldissera  
(800)368.1217

**Company Contact:**  
Molly Henderson  
Chief Financial Officer  
500 Linden Oaks  
Rochester, New York 14625  
(585)249.6231

**10<sup>th</sup> PATENT AWARDED TO VIRTUALSCOPICS**  
*Patent enables elimination of metal artifacts during CT imaging*

ROCHESTER, NY – April 21, 2008 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading developer of image-based biomarker solutions for the pharmaceutical, biotechnology and medical device industries, today announced it has received a notice of allowance for its 10<sup>th</sup> patent titled “System and Method for Reducing or Eliminating Streak Artifacts and Illumination Inhomogeneity in CT Imaging.”

VirtualScopics, Inc.’s chief scientific officer, Dr. Ed Ashton stated, “The applications of the technology underlying this patent are extremely useful during CT scans of patients who have undergone hip replacement surgery or spinal fusion.” He continued, “often in CT images it is difficult to identify anatomical structures due to the interference that is created by metal prosthetics. This patent enables us to remove the artifacts created by these devices to allow us to accurately and precisely measure the surrounding tissues.”

The company also announced the issuance of the previously awarded patent “Semi-Automated Measurement of Anatomical Structures Using Statistical and Morphological Priors.” Dr. Ashton further stated, “We are extremely pleased with the robustness of our patent portfolio. These proprietary tools are the basis for the services and information we provide our customers that enable them to make better and quicker decisions on the efficacy of their compounds.”

**About VirtualScopics, Inc.**

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit [www.virtualscopics.com](http://www.virtualscopics.com).



**Forward-Looking Statements**

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.